Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of PM14 Alone and with Radiotherapy for Patients with Advanced Soft Tissue Sarcomas and Other Solid Tumors

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called PM14 on certain types of cancers known as soft tissue sarcomas and other solid tumors. Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. Solid tumors refer to abnormal masses of tissue that usually do not contain cysts or liquid areas. The treatment being tested, PM14, is a medication that is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of this study is to explore different ways of using PM14, both on its own and in combination with radiotherapy, which is a treatment that uses high doses of radiation to kill cancer cells and shrink tumors. The study is divided into different groups, or cohorts, each testing a specific treatment plan. Some groups will receive PM14 alone, while others will receive PM14 along with radiotherapy. The study aims to find the best dose of PM14 that can be safely used and to see how well it works in stopping the cancer from growing or spreading.

Participants in the study will receive PM14 in different schedules, such as a 24-hour infusion or shorter infusions over consecutive days. The study will also look at how the treatment affects the participants' quality of life and any side effects they may experience. The trial will provide valuable information about the potential benefits and risks of PM14 for treating these types of cancers, helping to determine if it could be a useful option for patients in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    Upon joining the study, the patient will begin treatment with PM14, a medication administered through a vein (intravenous).

    The medication is provided as a powder that is mixed into a solution for infusion.

  2. Step 2

    Treatment schedule

    The treatment involves different schedules depending on the cohort:

    Cohorts A and E: PM14 is given over 24 hours.

    Cohorts B and F: PM14 is given over 3 hours for 3 consecutive days.

    Cohort C: PM14 is combined with radiotherapy, which involves 3 Gy of radiation for 10 days, totaling 30 Gy.

    Cohort D: PM14 is combined with a different radiotherapy schedule, involving 1.8 Gy of radiation for 25 days, totaling 45 Gy.

  3. Step 3

    Monitoring and assessments

    Throughout the trial, the patient's response to treatment will be monitored through regular assessments.

    These assessments include physical examinations, laboratory tests, and imaging studies to evaluate the size and progression of tumors.

    The patient's quality of life will also be assessed using a questionnaire.

  4. Step 4

    Evaluation of treatment response

    The effectiveness of the treatment will be evaluated by measuring the progression-free survival rate at 6 months for certain cohorts.

    For other cohorts, the overall response rate will be assessed, focusing on the reduction in tumor size or complete disappearance of the tumor.

  5. Step 5

    End of treatment

    The trial is expected to conclude by December 19, 2025.

    At the end of the treatment period, a final assessment will be conducted to determine the overall outcomes and any long-term effects of the treatment.

Who can join the trial?

20 criteria

  • Patients must voluntarily sign the informed consent before any study test is conducted that is not part of routine patient care.
  • Patients must have a diagnosis of advanced soft tissue sarcoma, or recurrent head and neck cancer suitable for reirradiation, or other advanced or metastatic solid tumor not suitable for surgery. A centralized diagnosis will be performed, and the tumor sample must be available and sent before starting treatment.
  • Patients must have received a previous chemotherapy treatment for advanced disease.
  • A centralized diagnosis of sarcoma is required, which includes specific types like undifferentiated pleomorphic sarcoma, leiomyosarcoma, and others.
  • Disease distribution must allow meeting normal tissue constraints of radiation therapy, confirmed by a radiation oncologist.
  • Metastatic spread could be present in several organs, but not all locations need to be irradiated.
  • Lesions considered for radiation therapy should be related to symptoms.
  • Not all lesions need to be under radiation fields, but priority is given to those with greater size increase and those related to symptoms.
  • Radiological disease progression must be documented within 6 months before study entry.
  • Patients must be eligible for systemic chemotherapy, with a maximum of three previous treatments for advanced/metastatic disease allowed.
  • Normal heart function is required, with a left ventricular ejection fraction (LVEF) of at least 50%.
  • Age must be between 18 and 75 years.
  • Measurable disease according to specific criteria is required.
  • Performance status must be 0 or 1, which indicates the patient's ability to perform daily activities.
  • Men and women of childbearing potential must use effective contraception before and during the study, and for a period after the study ends. Women must have a negative pregnancy test before entering the study.
  • Patients must have a diagnosis of localized soft tissue sarcoma with specific risk criteria.
  • Patients must be diagnosed by core-biopsy, with the time between biopsy and enrollment being less than 6 weeks.
  • Patients must have a central venous catheter for treatment.
  • Patients must have a diagnosis of soft tissue sarcoma with metastasis, not suitable for surgery, with a centralized diagnosis confirmation.
  • HBV and HCV serologies must be performed before inclusion. If positive, further testing or preventive treatment may be required.

Who cannot join the trial?

15 criteria

  • Patients who are not able to understand or follow the study instructions.
  • Patients who have a medical condition that could interfere with the study results.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had another type of cancer in the past, unless it was treated and cured.
  • Patients who are pregnant or breastfeeding.
  • Patients who have an infection that is not well controlled.
  • Patients who have a history of severe allergic reactions.
  • Patients who have a serious heart condition.
  • Patients who have a serious liver or kidney disease.
  • Patients who have a mental health condition that could interfere with the study.
  • Patients who have used certain medications that could affect the study results.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have had a major surgery recently.
  • Patients who have a condition that affects their immune system.
  • Patients who have a blood disorder that affects clotting.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • PM14

    is an investigational medication being studied for its potential use in treating advanced sarcomas and other solid tumors. It is being tested in different dosing schedules to find the most effective and tolerable way to administer it. The goal is to determine the maximum dose that patients can tolerate and to evaluate how well it works in stopping the progression of the disease.

  • Radiotherapy

    is a treatment that uses high doses of radiation to kill cancer cells and shrink tumors. In this trial, radiotherapy is combined with PM14 to see if the combination is more effective than PM14 alone. The radiotherapy is given in specific doses over a set number of days, depending on the type of cancer being treated. The aim is to assess the response of the tumors to this combined treatment and to provide relief from symptoms.

What is already known about the treatment

PM14 – PM14 is administered intravenously, either as a 24-hour infusion or a 3-hour infusion over three consecutive days. It is currently being studied in clinical trials for its effectiveness in treating soft tissue sarcomas and other solid tumors. The main therapeutic indication for PM14 is to manage advanced sarcomas and solid tumors, potentially in combination with radiotherapy. At the molecular level, PM14 works by interfering with cancer cell growth and division, although the exact mechanism is still under investigation. It is classified pharmacologically as an investigational anti-cancer agent.

Investigated diseases

  • Soft Tissue Sarcomas

    Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. These tissues include muscle, fat, blood vessels, nerves, tendons, and the lining of the joints. The disease can occur anywhere in the body but is most commonly found in the arms, legs, and trunk. As the sarcoma grows, it may cause a noticeable lump or swelling. Over time, it can invade nearby tissues and spread to other parts of the body. The progression of the disease varies depending on the type and location of the sarcoma.

  • Solid Tumors

    Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in any organ or tissue, including the bones, muscles, and organs. Unlike blood cancers, solid tumors form a mass and can be benign (non-cancerous) or malignant (cancerous). As they grow, they may press on nearby organs, nerves, and blood vessels, causing symptoms. The growth rate and spread of solid tumors depend on their type and location. Malignant solid tumors can invade surrounding tissues and metastasize to distant parts of the body.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-519893-38-00Estimated enrolment195 patientsSponsorAsoc Grupo Espanol De Investigacion En Sarcomas

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).